1. Home
  2. FULC vs NCV Comparison

FULC vs NCV Comparison

Compare FULC & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.69

Market Cap

281.1M

Sector

Health Care

ML Signal

N/A

Logo Virtus Convertible & Income Fund of Beneficial Interest

NCV

Virtus Convertible & Income Fund of Beneficial Interest

N/A

Current Price

$13.32

Market Cap

337.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
FULC
NCV
Founded
2015
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
281.1M
337.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
FULC
NCV
Price
$3.69
$13.32
Analyst Decision
Hold
Analyst Count
5
0
Target Price
★ $3.67
N/A
AVG Volume (30 Days)
★ 1.2M
62.4K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
★ 12.48%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.83
$13.55
52 Week High
$15.74
$17.65

Technical Indicators

Market Signals
Indicator
FULC
NCV
Relative Strength Index (RSI) 45.53 23.84
Support Level $3.62 N/A
Resistance Level $3.81 $16.75
Average True Range (ATR) 0.06 0.32
MACD -0.00 -0.12
Stochastic Oscillator 7.69 3.48

Price Performance

Historical Comparison
FULC
NCV

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

About NCV Virtus Convertible & Income Fund of Beneficial Interest

Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.

Share on Social Networks: